Aerie reports $14.5 million net loss for quarter, advances Rhopressa study

Notwithstanding a total adjusted net loss of $14.5 million in the first quarter of 2015 and failure of Rhopressa to meet its primary endpoint in clinical trial, Aerie Pharmaceuticals believes in the potential of its once-daily, triple-action, IOP-lowering eye drop.In a company-sponsored conference call to report first quarter financial status and company intentions, chairman and CEO Vicente Anido Jr., PhD, discussed recently released results of the initial phase 3 Rocket 1 clinical trial for Rhopressa.